
## Sergey N Mosolov

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5147823/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Validation of the Russian version of Stress and Anxiety to Viral Epidemics – 9 items (SAVE-9) among healthcare workers during COVID-19 pandemic. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2022, 14, 45-51.	1.2	0
2	The risk of developing cardiovascular disease in bipolar disorder. Biological factors and therapy. Terapevticheskii Arkhiv, 2022, 94, 579-583.	0.8	1
3	Characterization of rapid cycling bipolar patients presenting with major depressive episode within the BRIDGEâ€IIâ€MIX study. Bipolar Disorders, 2021, 23, 391-399.	1.9	7
4	Electroconvulsive Therapy (ECT) in Bipolar Disorder Patients with Ultra-Rapid Cycling and Unstable Mixed States. Medicina (Lithuania), 2021, 57, 624.	2.0	4
5	Incidence of the Diagnosis of Anxiety Disorders in the Russian Federation: Results of a Web-Based Survey of Psychiatrists. Neurology and Therapy, 2021, 10, 971-984.	3.2	1
6	Stress, anxiety, depression and burnout in frontline healthcare workers during two peaks of COVID-19 pandemic in Russia. Psychiatry Research, 2021, 306, 114226.	3.3	27
7	Functioning Problems in Persons with Schizophrenia in the Russian Context. International Journal of Environmental Research and Public Health, 2021, 18, 10276.	2.6	0
8	Questionnaire for initial self-assessment in post-COVID period: Recommendations of Multidisciplinary expert board on screening of post-COVID syndrome during an expanded medical check-up. Pulmonologiya, 2021, 31, 599-612.	0.8	0
9	Primary and Secondary Negative Symptoms in Schizophrenia. Frontiers in Psychiatry, 2021, 12, 766692.	2.6	31
10	The electroencephalographic profile of depressions with atypical features in recurrent depressive and bipolar affective type II disorders. Russian Psychiatric Journal, 2021, , 59-72.	0.2	0
11	Screening for hypomania among patients with recurrent depression using the new HCL-33 questionnaire. Russian Psychiatric Journal, 2021, , 59-69.	0.2	0
12	The risk of developing cardiovascular disease in bipolar disorder. Clinical and social factors. Terapevticheskii Arkhiv, 2021, 93, 1556-1561.	0.8	4
13	Depression with Mixed Features (for DSM-5): Distinguishing Indicators Imaginary Coherence EEG Rest. Psychiatry, 2021, 19, 61-75.	0.7	0
14	"Do depressive and manic symptoms differentially impact on functioning in acute depression? Results from a large, cross-sectional study― Journal of Affective Disorders, 2020, 261, 30-39.	4.1	11
15	Deconstructing major depressive episodes across unipolar and bipolar depression by severity and duration: a cross-diagnostic cluster analysis on a large, international, observational study. Translational Psychiatry, 2020, 10, 241.	4.8	9
16	Factors associated with single versus multiple suicide attempts in depressive disorders. Journal of Affective Disorders, 2020, 277, 306-312.	4.1	13
17	Symptom networks in acute depression across bipolar and major depressive disorders: A network analysis on a large, international, observational study. European Neuropsychopharmacology, 2020, 35, 49-60.	0.7	18
18	STRESS AND ANXIETY AMONG HEALTHCARE WORKERS ASSOCIATED WITH COVID-19 PANDEMIC IN RUSSIA. Psychiatria Danubina, 2020, 32, 549-556.	0.4	27

SERGEY N MOSOLOV

#	Article	IF	CITATIONS
19	The role of different patterns of psychomotor symptoms in major depressive episode: Pooled analysis of the BRIDGE and BRIDGEâ€IIâ€MIX cohorts. Bipolar Disorders, 2019, 21, 785-793.	1.9	7
20	Patterns of response to antidepressants in major depressive disorder: Drug resistance or worsening of depression are associated with a bipolar diathesis. European Neuropsychopharmacology, 2019, 29, 825-834.	0.7	41
21	Relationships between recurrence and polarity in major depressive disorders: Pooled analysis of the BRIDGE and BRIDGE-II-MIX cohorts. Journal of Affective Disorders, 2019, 256, 250-258.	4.1	11
22	The role of overlapping excitatory symptoms in major depression: are they relevant for the diagnosis of mixed state?. Journal of Psychiatric Research, 2019, 115, 151-157.	3.1	27
23	The implications of hypersomnia in the context of major depression: Results from a large, international, observational study. European Neuropsychopharmacology, 2019, 29, 471-481.	0.7	24
24	The relationship between attention deficit hyperactivity disorder, bipolarity and mixed features in major depressive patients: Evidence from the BRIDGE-II-Mix Study. Journal of Affective Disorders, 2019, 246, 346-354.	4.1	14
25	Sultans of Swing. Journal of Clinical Psychiatry, 2019, 80, .	2.2	12
26	Is recurrence in major depressive disorder related to bipolarity and mixed features? Results from the BRIDGE-II-Mix study. Journal of Affective Disorders, 2018, 229, 164-170.	4.1	28
27	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Acute and long-term treatment of mixed states in bipolar disorder. World Journal of Biological Psychiatry, 2018, 19, 2-58.	2.6	128
28	12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25–50â€~mg/day) versus escitalopram (10–20â€~mg/day) in out-patients with severe generalized anxiety disorder. European Neuropsychopharmacology, 2018, 28, 970-979.	0.7	25
29	THE COMBINED EFFECT OF CYP2D6 AND DRD2 Taq1A POLYMORPHISMS ON THE ANTIPSYCHOTICS DAILY DOSES AND HOSPITAL STAY DURATION IN SCHIZOPHRENIA INPATIENTS (OBSERVATIONAL NATURALISTIC) TJ ET	Qq <b>1.4</b> 1 0.78	84314 rgB⊺
30	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia – a short version for primary care. International Journal of Psychiatry in Clinical Practice, 2017, 21, 82-90.	2.4	61
31	Antidepressant-induced hypomania/mania in patients with major depression: Evidence from the BRIDCE-II-MIX study. Journal of Affective Disorders, 2017, 219, 187-192.	4.1	47
32	Obesity in patients with major depression is related to bipolarity and mixed features: evidence from the <scp>BRIDGE</scp> â€ <scp>II</scp> â€ <scp>Mix</scp> study. Bipolar Disorders, 2017, 19, 458-464.	1.9	34
33	Aggressiveness in depression: a neglected symptom possibly associated with bipolarity and mixed features. Acta Psychiatrica Scandinavica, 2017, 136, 362-372.	4.5	31
34	Dynamics of Electroencephalogram Spectral Characteristics during Use of Transcranial Magnetic Stimulation in Patients with Refractory Depression. Neuroscience and Behavioral Physiology, 2017, 47, 281-287.	0.4	0
35	Relationships between mixed features and borderline personality disorder in 2811 patients with major depressive episode. Acta Psychiatrica Scandinavica, 2016, 133, 133-143.	4.5	27
36	Suicide attempts in major depressive episode: evidence from the <scp>BRIDGE</scp> â€ <scp>II</scp> â€Mix study. Bipolar Disorders, 2015, 17, 795-803.	1.9	91

SERGEY N MOSOLOV

#	Article	IF	CITATIONS
37	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation. World Journal of Biological Psychiatry, 2015, 16, 142-170.	2.6	106
38	Mixed Features in Patients With a Major Depressive Episode. Journal of Clinical Psychiatry, 2015, 76, e351-e358.	2.2	136
39	G.Ya. Avrutsky — a founder of Russian clinical paychopharmacology (to 90th anniversary of birth). Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova, 2015, 115, 60.	0.7	1
40	Towards a framework for treatment effectiveness in schizophrenia. Neuropsychiatric Disease and Treatment, 2014, 10, 1867.	2.2	18
41	Design and validation of standardized clinical and functional remission criteria in schizophrenia. Neuropsychiatric Disease and Treatment, 2014, 10, 167.	2.2	19
42	Bipolar <scp>II</scp> disorder in patients with a current diagnosis of recurrent depression. Bipolar Disorders, 2014, 16, 389-399.	1.9	26
43	Validation of the Russian version of the Hypomania Checklist (HCL-32) for the detection of Bipolar II disorder in patients with a current diagnosis of recurrent depression. Journal of Affective Disorders, 2014, 155, 90-95.	4.1	30
44	A placebo-controlled study of three agomelatine dose regimens (10mg, 25mg, 25–50mg) in patients with major depressive disorder. European Neuropsychopharmacology, 2014, 24, 553-563.	0.7	26
45	Management of schizophrenia: clinical experience with asenapine. Journal of Psychopharmacology, 2013, 27, 14-22.	4.0	10
46	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2012 on the long-term treatment of bipolar disorder. World Journal of Biological Psychiatry, 2013, 14, 154-219.	2.6	344
47	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World Journal of Biological Psychiatry, 2013, 14, 2-44.	2.6	343
48	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World Journal of Biological Psychiatry, 2012, 13, 318-378.	2.6	498
49	Remission in schizophrenia: results of cross-sectional with 6-month follow-up period and 1-year observational therapeutic studies in an outpatient population. Annals of General Psychiatry, 2012, 11, 1.	2.7	31
50	mGlu2/3 Agonists – a New Approach to the Treatment of Schizophrenia: Results of a Randomized Double-Blind Trial. Neuroscience and Behavioral Physiology, 2011, 41, 559-566.	0.4	1
51	Efficacy of valproate versus lithium in mania or mixed mania: a randomized, open 12-week trial. International Clinical Psychopharmacology, 2010, 25, 60-67.	1.7	59
52	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. World Journal of Biological Psychiatry, 2010, 11, 81-109.	2.6	322
53	REMISSION IN SCHIZOPHRENIA: RESULTS OF POPULATION AND PHARMACOTHERAPEUTIC STUDIES OF SCHIZOPHRENIC OUTPATIENTS. Schizophrenia Research, 2010, 117, 495-496.	2.0	2
54	Intramuscular olanzapine vs. intramuscular short-acting antipsychotics: safety, tolerability and the switch to oral antipsychotic medication in patients with schizophrenia or acute mania. International Journal of Clinical Practice, 2009, 63, 1249-1258.	1.7	20

#	Article	IF	CITATIONS
55	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2009 on the Treatment of Acute Mania. World Journal of Biological Psychiatry, 2009, 10, 85-116.	2.6	302
56	Repetitive Transcranial Magnetic Stimulation (rTMS) for the treatment of depression in schizophrenia patients. Annals of General Psychiatry, 2008, 7, .	2.7	2
57	Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nature Medicine, 2007, 13, 1102-1107.	30.7	1,003
58	Psychiatry in selected countries of Central and Eastern Europe: an overview of the current situation. Acta Psychiatrica Scandinavica, 2006, 114, 223-231.	4.5	26
59	Quetiapine in the treatment of patients with resistant auditory hallucinations: two case reports with long-term cognitive assessment. European Psychiatry, 2005, 20, 430-430.	0.2	4